Wu XY - Search Results

1

Combining Tumor Microenvironment Modulating Nanoparticles with Doxorubicin to Enhance Chemotherapeutic Efficacy and Boost Antitumor Immunity.

Amini MA, Abbasi AZ, Cai P, Lip H, Gordijo CR, Li J, Chen B, Zhang L, Rauth AM, Wu XY. Amini MA, et al. Among authors: wu xy. J Natl Cancer Inst. 2019 Apr 1;111(4):399-408. doi: 10.1093/jnci/djy131. J Natl Cancer Inst. 2019. PMID: 30239773

2

Screening of lipid carriers and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles (PLN).

Li Y, Taulier N, Rauth AM, Wu XY. Li Y, et al. Among authors: wu xy. Pharm Res. 2006 Aug;23(8):1877-87. doi: 10.1007/s11095-006-9033-2. Pharm Res. 2006. PMID: 16850265

3

Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.

Wong HL, Bendayan R, Rauth AM, Wu XY. Wong HL, et al. Among authors: wu xy. J Control Release. 2006 Dec 1;116(3):275-84. doi: 10.1016/j.jconrel.2006.09.007. Epub 2006 Sep 26. J Control Release. 2006. PMID: 17097178

4

In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.

Wong HL, Rauth AM, Bendayan R, Wu XY. Wong HL, et al. Among authors: wu xy. Eur J Pharm Biopharm. 2007 Mar;65(3):300-8. doi: 10.1016/j.ejpb.2006.10.022. Epub 2006 Nov 7. Eur J Pharm Biopharm. 2007. PMID: 17156986

5

Immobilization and bioactivity of glucose oxidase in hydrogel microspheres formulated by an emulsification-internal gelation-adsorption-polyelectrolyte coating method.

Liu Q, Rauth AM, Wu XY. Liu Q, et al. Among authors: wu xy. Int J Pharm. 2007 Jul 18;339(1-2):148-56. doi: 10.1016/j.ijpharm.2007.02.027. Epub 2007 Mar 1. Int J Pharm. 2007. PMID: 17398046

6

Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles.

Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Wong HL, et al. Among authors: wu xy. Adv Drug Deliv Rev. 2007 Jul 10;59(6):491-504. doi: 10.1016/j.addr.2007.04.008. Epub 2007 May 1. Adv Drug Deliv Rev. 2007. PMID: 17532091 Review.

7

Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles.

Li Y, Wong HL, Shuhendler AJ, Rauth AM, Wu XY. Li Y, et al. Among authors: wu xy. J Control Release. 2008 May 22;128(1):60-70. doi: 10.1016/j.jconrel.2008.02.014. Epub 2008 Mar 5. J Control Release. 2008. PMID: 18406489

8

On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells.

Shuhendler AJ, O'Brien PJ, Rauth AM, Wu XY. Shuhendler AJ, et al. Among authors: wu xy. Drug Metabol Drug Interact. 2007;22(4):201-33. doi: 10.1515/dmdi.2007.22.4.201. Drug Metabol Drug Interact. 2007. PMID: 18447000

9

A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.

Shuhendler AJ, Cheung RY, Manias J, Connor A, Rauth AM, Wu XY. Shuhendler AJ, et al. Among authors: wu xy. Breast Cancer Res Treat. 2010 Jan;119(2):255-69. doi: 10.1007/s10549-008-0271-3. Epub 2009 Feb 17. Breast Cancer Res Treat. 2010. PMID: 19221875

10

Cytotoxicity and mechanism of action of a new ROS-generating microsphere formulation for circumventing multidrug resistance in breast cancer cells.

Liu Q, Shuhendler A, Cheng J, Rauth AM, O'Brien P, Wu XY. Liu Q, et al. Among authors: wu xy. Breast Cancer Res Treat. 2010 Jun;121(2):323-33. doi: 10.1007/s10549-009-0473-3. Epub 2009 Jul 18. Breast Cancer Res Treat. 2010. PMID: 19618264

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,765 results

Search Page

Filters